Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis
Abstract Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the TTR gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. W...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2021-11-01
|
| Series: | Neurological Research and Practice |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s42466-021-00155-8 |
| _version_ | 1818986018950348800 |
|---|---|
| author | Maike F. Dohrn Jessica Medina Karmele R. Olaciregui Dague Ernst Hund |
| author_facet | Maike F. Dohrn Jessica Medina Karmele R. Olaciregui Dague Ernst Hund |
| author_sort | Maike F. Dohrn |
| collection | DOAJ |
| description | Abstract Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the TTR gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. With 90% of the amyloidogenic protein produced by the liver, disease progression including polyneuropathy and cardiomyopathy, the two most prominent manifestations, can successfully be halted by hepatic drug targeting or—formerly—liver transplantation. Certain TTR variants, however, favor disease manifestations in the central nervous system (CNS) or eyes, which is mostly associated with TTR production in the choroid plexus and retina. These compartments cannot be sufficiently reached by any of the approved medications. From liver-transplanted patients, we have learned that with longer lifespans, such CNS manifestations become more relevant over time, even if the underlying TTR mutation is not primarily associated with such. Are we therefore creating a new phenotype? Prolonging life will most likely lead to a shift in the phenotypic spectrum, enabling manifestations like blindness, dementia, and cerebral hemorrhage to come out of the disease background. To overcome the first therapeutic limitation, the blood–brain barrier, we might be able to learn from other antisense drugs currently being used in research or even being approved for primary neurodegenerative CNS diseases like spinal muscular atrophy or Alzheimer’s disease. But what effects will unselective CNS TTR knock-down have considering its role in neuroprotection? A potential approach to overcome this second limitiation might be allele-specific targeting, which is, however, still far from clinical trials. Ethical standpoints underline the need for seamless data collection to enable more evidence-based decisions and for thoughtful consenting in research and clinical practice. We conclude that the current advances in treating ATTRv amyloidosis have become a meaningful example for mechanism-based treatment. With its great success in improving patient life spans, we will still have to face new challenges including shifts in the phenotype spectrum and the ongoing need for improved treatment precision. Further investigation is needed to address these closed barriers and open questions. |
| first_indexed | 2024-12-20T18:44:08Z |
| format | Article |
| id | doaj.art-9fb44f289ffd423bb7e7aa14a4bebefc |
| institution | Directory Open Access Journal |
| issn | 2524-3489 |
| language | English |
| last_indexed | 2024-12-20T18:44:08Z |
| publishDate | 2021-11-01 |
| publisher | BMC |
| record_format | Article |
| series | Neurological Research and Practice |
| spelling | doaj.art-9fb44f289ffd423bb7e7aa14a4bebefc2022-12-21T19:29:45ZengBMCNeurological Research and Practice2524-34892021-11-013111110.1186/s42466-021-00155-8Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosisMaike F. Dohrn0Jessica Medina1Karmele R. Olaciregui Dague2Ernst Hund3Department of Neurology, Medical Faculty of the RWTH Aachen University, Neuromuscular Outpatient Clinic, University Hospital AachenDr. John T. Macdonald Foundation, Department of Human Genetics and John P. Hussman Institute for Human Genomics, University of Miami, Miller School of MedicineDepartment of Epileptology, Medical Faculty, University Hospital BonnAmyloidosis Center Heidelberg, Heidelberg University HospitalAbstract Hereditary transthyretin (TTR) amyloidosis (ATTRv) is an autosomal dominant, systemic disease transmitted by amyloidogenic mutations in the TTR gene. To prevent the otherwise fatal disease course, TTR stabilizers and mRNA silencing antisense drugs are currently approved treatment options. With 90% of the amyloidogenic protein produced by the liver, disease progression including polyneuropathy and cardiomyopathy, the two most prominent manifestations, can successfully be halted by hepatic drug targeting or—formerly—liver transplantation. Certain TTR variants, however, favor disease manifestations in the central nervous system (CNS) or eyes, which is mostly associated with TTR production in the choroid plexus and retina. These compartments cannot be sufficiently reached by any of the approved medications. From liver-transplanted patients, we have learned that with longer lifespans, such CNS manifestations become more relevant over time, even if the underlying TTR mutation is not primarily associated with such. Are we therefore creating a new phenotype? Prolonging life will most likely lead to a shift in the phenotypic spectrum, enabling manifestations like blindness, dementia, and cerebral hemorrhage to come out of the disease background. To overcome the first therapeutic limitation, the blood–brain barrier, we might be able to learn from other antisense drugs currently being used in research or even being approved for primary neurodegenerative CNS diseases like spinal muscular atrophy or Alzheimer’s disease. But what effects will unselective CNS TTR knock-down have considering its role in neuroprotection? A potential approach to overcome this second limitiation might be allele-specific targeting, which is, however, still far from clinical trials. Ethical standpoints underline the need for seamless data collection to enable more evidence-based decisions and for thoughtful consenting in research and clinical practice. We conclude that the current advances in treating ATTRv amyloidosis have become a meaningful example for mechanism-based treatment. With its great success in improving patient life spans, we will still have to face new challenges including shifts in the phenotype spectrum and the ongoing need for improved treatment precision. Further investigation is needed to address these closed barriers and open questions.https://doi.org/10.1186/s42466-021-00155-8Central nervous system amyloidosisEye involvementBlood–brain barrierLiver transplantationAntisense oligonucleotidesSmall interfering RNA |
| spellingShingle | Maike F. Dohrn Jessica Medina Karmele R. Olaciregui Dague Ernst Hund Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis Neurological Research and Practice Central nervous system amyloidosis Eye involvement Blood–brain barrier Liver transplantation Antisense oligonucleotides Small interfering RNA |
| title | Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis |
| title_full | Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis |
| title_fullStr | Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis |
| title_full_unstemmed | Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis |
| title_short | Are we creating a new phenotype? Physiological barriers and ethical considerations in the treatment of hereditary transthyretin-amyloidosis |
| title_sort | are we creating a new phenotype physiological barriers and ethical considerations in the treatment of hereditary transthyretin amyloidosis |
| topic | Central nervous system amyloidosis Eye involvement Blood–brain barrier Liver transplantation Antisense oligonucleotides Small interfering RNA |
| url | https://doi.org/10.1186/s42466-021-00155-8 |
| work_keys_str_mv | AT maikefdohrn arewecreatinganewphenotypephysiologicalbarriersandethicalconsiderationsinthetreatmentofhereditarytransthyretinamyloidosis AT jessicamedina arewecreatinganewphenotypephysiologicalbarriersandethicalconsiderationsinthetreatmentofhereditarytransthyretinamyloidosis AT karmelerolacireguidague arewecreatinganewphenotypephysiologicalbarriersandethicalconsiderationsinthetreatmentofhereditarytransthyretinamyloidosis AT ernsthund arewecreatinganewphenotypephysiologicalbarriersandethicalconsiderationsinthetreatmentofhereditarytransthyretinamyloidosis |